Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Using Big Data in oncology to prospectively impact clinical patient care: A proof of concept study.

Dougoud-Chauvin V, Lee JJ, Santos E, Williams VL, Battisti NML, Ghia K, Sehovic M, Croft C, Kim J, Balducci L, Kish JA, Extermann M.

J Geriatr Oncol. 2018 Apr 17. pii: S1879-4068(18)30130-9. doi: 10.1016/j.jgo.2018.03.017. [Epub ahead of print]

PMID:
29678669
2.

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC.

J Clin Oncol. 2018 May 10;36(14):1412-1418. doi: 10.1200/JCO.2017.77.0388. Epub 2018 Mar 27.

PMID:
29584545
3.

The Older Adult With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: Knowledge Gaps and Future Direction in Assessment and Treatment.

Maggiore R, Zumsteg ZS, BrintzenhofeSzoc K, Trevino KM, Gajra A, Korc-Grodzicki B, Epstein JB, Bond SM, Parker I, Kish JA, Murphy BA, VanderWalde NA; CARG-HNC Study Group.

Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):868-883. doi: 10.1016/j.ijrobp.2017.02.022. Review.

4.

Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years.

Strom TJ, Naghavi AO, Trotti AM, Russell J, Kish JA, McCaffrey J, Otto KJ, Harrison LB, Caudell JJ.

J Geriatr Oncol. 2017 Jan;8(1):50-55. doi: 10.1016/j.jgo.2016.09.003. Epub 2016 Oct 3.

PMID:
27720129
5.

Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer.

Frakes JM, Naghavi AO, Demetriou SK, Strom TJ, Russell JS, Kish JA, McCaffrey JC, Otto KJ, Padhya TA, Harrison LB, Trotti AM, Caudell JJ.

Cancer. 2016 Feb 15;122(4):634-41. doi: 10.1002/cncr.29782. Epub 2015 Nov 13.

6.

Effect of prophylactic fluconazole on oral mucositis and candidiasis during radiation therapy for head-and-neck cancer.

Rao NG, Han G, Greene JN, Tanvetyanon T, Kish JA, De Conti RC, Chuong MD, Shridhar R, Biagioli MC, Caudell JJ, Trotti AM 3rd.

Pract Radiat Oncol. 2013 Jul-Sep;3(3):229-233. doi: 10.1016/j.prro.2012.05.008. Epub 2012 Jun 21.

PMID:
24674369
7.

Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck.

Tanvetyanon T, Padhya T, McCaffrey J, Kish JA, Deconti RC, Trotti A, Rao NG.

Head Neck. 2015 Jun;37(6):840-5. doi: 10.1002/hed.23684. Epub 2014 Jun 27.

PMID:
24623654
8.

A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.

Gray JE, Haura E, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenck M, Kish JA, Kreahling J, Lush R, Neuger A, Tetteh L, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S.

Clin Cancer Res. 2014 Mar 15;20(6):1644-55. doi: 10.1158/1078-0432.CCR-13-2235. Epub 2014 Jan 15.

9.

Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck.

Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK.

Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1198-205. doi: 10.1016/j.ijrobp.2012.05.008. Epub 2012 Jun 30.

10.

A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149).

Swinnen LJ, Rankin C, Carraway H, Albain KS, Townsend JJ, Budd GT, Kish JA, Rivkin SE, Blumenthal DT.

J Neurooncol. 2008 Feb;86(3):353-8. doi: 10.1007/s11060-007-9483-3. Epub 2007 Nov 16.

11.

Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.

Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK; Radiation Therapy Oncology Group 9501/Intergroup.

N Engl J Med. 2004 May 6;350(19):1937-44.

12.

An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.

Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA.

J Clin Oncol. 2003 Jan 1;21(1):92-8.

PMID:
12506176
13.

The treatment challenge of hormone-refractory prostate cancer.

Kish JA, Bukkapatnam R, Palazzo F.

Cancer Control. 2001 Nov-Dec;8(6):487-95. Review.

PMID:
11807418
14.

Neoadjuvant androgen ablation in localized carcinoma of the prostate.

Kish JA.

Cancer Control. 2001 Mar-Apr;8(2):155-62. Review.

PMID:
11326170
15.

Feasibility trial of postoperative radiotherapy and cisplatin followed by three courses of 5-FU and cisplatin in patients with resected head and neck cancer: a Southwest Oncology Group study.

Kish JA, Benedetti JK, Balcerzak SP, Veith RW, Davis R, Pollock TW, Schuller DE, Ensley JF.

Cancer J Sci Am. 1999 Sep-Oct;5(5):307-11.

PMID:
10526672
16.

Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial.

Kish JA, Wolf MK, Schellhammer PF, Hussain MH, Einstein AB, Crawford ED.

Am J Clin Oncol. 1997 Aug;20(4):327-30.

PMID:
9256883
17.

Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

DiBenedetto J Jr, Cubeddu LX, Ryan T, Kish JA, Sciortino D, Beall C, Eisenberg PD, Henderson C, Griffin D, Wentz A.

Clin Ther. 1995 Nov-Dec;17(6):1091-8.

PMID:
8750400
18.

Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study.

Kish JA, Wolf M, Crawford ED, Leimert JT, Bueschen A, Neefe JR, Flanigan RC.

Cancer. 1994 Aug 1;74(3):916-9.

PMID:
8039119
19.

A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis.

Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ, Kish JA, Murphy WK, Hainsworth JD, Haley B.

J Clin Oncol. 1994 Mar;12(3):596-600.

PMID:
8120559
20.

Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.

Beck TM, Hesketh PJ, Madajewicz S, Navari RM, Pendergrass K, Lester EP, Kish JA, Murphy WK, Hainsworth JD, Gandara DR, et al.

J Clin Oncol. 1992 Dec;10(12):1969-75.

PMID:
1453211
21.

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.

Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK, et al.

J Clin Oncol. 1992 Aug;10(8):1245-51.

PMID:
1634913
22.

The incidence and significance of thromboembolic complications in patients with high-grade gliomas.

Cheruku R, Tapazoglou E, Ensley J, Kish JA, Cummings GD, al-Sarraf M.

Cancer. 1991 Dec 15;68(12):2621-4.

PMID:
1933812
23.

Phase II evaluation of amonafide in renal cell carcinoma. A Southwest Oncology Group study.

Higano CS, Goodman P, Craig JB, Kish JA, Rivkin SE, Wolf M, Crawford ED.

Invest New Drugs. 1991 Nov;9(4):361-3.

PMID:
1804814
24.

The Wayne State University experience with adjuvant chemotherapy of head and neck cancer.

al-Sarraf M, Kish JA, Ensley JF.

Hematol Oncol Clin North Am. 1991 Aug;5(4):687-700. Review.

PMID:
1890060
25.

The role of infection in the morbidity and mortality of patients with head and neck cancer undergoing multimodality therapy.

Hussain M, Kish JA, Crane L, Uwayda A, Cummings G, Ensley JF, Tapazoglou E, al-Sarraf M.

Cancer. 1991 Feb 1;67(3):716-21.

PMID:
1985764
26.

Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group study.

Kish JA, Kopecky K, Samson MK, Von Hoff DD, Fletcher WS, Kempf RA, Muggia FM.

Invest New Drugs. 1991 Feb;9(1):105-8.

PMID:
1709151
27.

Phase II study of continuous infusion recombinant gamma interferon in renal carcinoma. A Southwest Oncology Group study.

Kuebler JP, Goodman PJ, Brown TD, Crawford ED, Reitz CL, Knight WA 3rd, Kish JA.

Invest New Drugs. 1990 Aug;8(3):307-9. No abstract available.

PMID:
2125585
28.

Phase II evaluation of 4'deoxydoxorubicin in advanced renal cell carcinoma.

Kish JA, Ensley JF, al-Sarraf M.

Am J Clin Oncol. 1990 Feb;13(1):17-8.

PMID:
2305717
29.

Metastatic squamous cell carcinoma of an unknown primary localized to the neck. Advantages of an aggressive treatment.

de Braud F, Heilbrun LK, Ahmed K, Sakr W, Ensley JF, Kish JA, Tapazoglou E, al-Sarraf M.

Cancer. 1989 Jul 15;64(2):510-5.

PMID:
2736495
30.

Cellular DNA content parameters in untreated and recurrent squamous cell cancers of the head and neck.

Ensley JF, Maciorowski Z, Hassan M, Pietraszkiewicz H, Heilbrun L, Kish JA, Tapazoglou E, Jacobs JR, al-Sarraf M.

Cytometry. 1989 May;10(3):334-8.

31.
32.

The clinical syndrome of 5-fluorouracil cardiotoxicity.

Ensley JF, Patel B, Kloner R, Kish JA, Wynne J, al-Sarraf M.

Invest New Drugs. 1989 Apr;7(1):101-9.

PMID:
2737845
33.

Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer.

Kish JA, Ensley JF, Jacobs JR, Binns P, al-Sarraf M.

Am J Clin Oncol. 1988 Oct;11(5):553-7.

PMID:
3177258
34.

Chemotherapy for paranasal sinus carcinoma. A 10-year experience at Wayne State University.

LoRusso P, Tapazoglou E, Kish JA, Ensley JF, Cummings G, Kelly J, al-Sarraf M.

Cancer. 1988 Jul 1;62(1):1-5.

PMID:
2454717
35.

Proto-chemotherapy in advanced head and neck cancer.

Jacobs JR, Weaver A, Ahmed K, Crissman J, Ensley JF, Kish JA, Cummings G, al-Sarraf M.

Head Neck Surg. 1987 Nov-Dec;10(2):93-8.

PMID:
3333768
36.

Phase II evaluation of diaziquone in recurrent head and neck cancer.

Kish JA, Ensley J, Al-Sarraf M.

Cancer Treat Rep. 1986 May;70(5):671-2. No abstract available.

PMID:
3708616
37.
38.

The role of induction chemotherapy in advanced head and neck cancer: the Wayne State University experience.

Kish JA, Ensley J, Crissman J, Weaver A, Jacobs J, Kinzie J, Al-Sarraf M.

Prog Clin Biol Res. 1985;201:177-89. No abstract available.

PMID:
4095109
39.

Aclacinomycin. Phase II evaluation in advanced squamous carcinoma of the head and neck.

Kish JA, Al-Sarraf M.

Am J Clin Oncol. 1984 Oct;7(5):535-7.

PMID:
6507374
40.
41.
42.

Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck.

Kish JA, Weaver A, Jacobs J, Cummings G, Al-Sarraf M.

Cancer. 1984 May 1;53(9):1819-24.

PMID:
6538456
43.

Fatal syncytial virus pneumonia in a laminar airflow room.

Crane LR, Kish JA, Ratanatharathorn V, Merline JR, Raval MF.

JAMA. 1981 Jul 24-31;246(4):366-7. No abstract available.

PMID:
7241785
44.

Methods for storage and retrieval of scientific information.

Kish JA.

Bull Parenter Drug Assoc. 1976 Jan-Feb;30(1):26-6. No abstract available.

PMID:
1252654
45.

Gasket insert modification of U.S.P. tablet disintegration apparatus.

KAPLAN LL, KISH JA.

J Pharm Sci. 1962 Jul;51:706. No abstract available.

PMID:
14453757

Supplemental Content

Support Center